Fig. 1

E2F4 activity and response to neoadjuvant chemotherapy. a Distribution of E2F4 activity scores for all patients (grey), ER-positive patients (magenta), and ER-negative patients (aqua). Black dotted lines indicate thresholds at which low, intermediate, and high E2F4 activity patient groups were stratified on. Solid black line indicates the threshold to stratify patients into low and high E2F4 activity groups for subsequent survival analyses. b Patients with high E2F4 activity (red) were associated with significantly shorter distant recurrence free survival time (DRFS) compared to patients with low E2F4 scores (green). Vertical hash marks indicate censored patients. c Comparison of E2F4 activity scores between patients achieving pathological complete response (pCR) and patients with residual disease (RD). d Comparison of E2F4 activity between patients with varying residual cancer burden: RCB-0/1 (white), RCB-II (grey) and RCB-III (dark grey) e Percentages of pCR and RD patients in E2F4 activity groups. f Receiver Operating Characteristic (ROC) curves for pCR prediction using E2F4 activity scores as features and 10-fold cross validation. ROC curves were generated for all (black), ER-positive only (magenta), and ER-negative only (aqua) patients